Skip to main content

Table 1 Treatment and methods summary for animal studies

From: TNF-α blockade is ineffective in animal models of established polycystic kidney disease

Study

Genotype

Age at treatment

Animals per arm

Treatments

Administration route

Dose

Schedule

Treatment duration

ARPKD rat, short-term therapeutic intervention

PcK/Crljcrl-Pkhd1pck

4 weeks

10

Vehicle

NA

NA

NA

4 weeks

PcK/Crljcrl-Pkhd1pck

4 weeks

10

Mozavaptan

i.p.

0.5, 5, 10 mg/kg

Once, every third day

4 weeks

ARPKD rat, Long-term therapeutic intervention

PcK/Crljcrl-Pkhd1pck

4 weeks

10

Vehicle

NA

NA

NA

8 weeks

PcK/Crljcrl-Pkhd1pck

4 weeks

10

Mozavaptan

Milled chow

0.10%

ad libitum

8 weeks

PcK/Crljcrl-Pkhd1pck

4 weeks

10

Etanercept

i.p.

5 mg/kg

Once, every third day

8 weeks

ADPKD (PDK2 ws25/-) mouse, therapeutic intervention

PKD2 ws25/-

12 weeks

14

Vehicle

NA

NA

NA

8 weeks

PKD2 ws25/-

12 weeks

11

Mozavaptan

Milled chow

0.10%

ad libitum

8 weeks

PKD2 ws25/-

12 weeks

15

Etanercept

i.p.

5 mg/kg

Once, every third day

8 weeks

ADPKD (PDK2 ws25/-) mouse, prophylactic intervention

PKD2 ws25/-

4 weeks

15

Vehicle

NA

NA

NA

8 weeks

PKD2 ws25/-

4 weeks

15

Mozavaptan

Milled chow

0.05%

ad libitum

8 weeks

 

PKD2 ws25/-

4 weeks

15

Etanercept

i.p.

5, 10 mg/kg

Once, every third day

8 weeks